Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Launched by ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY · Dec 13, 2022
Trial Information
Current as of May 18, 2025
Unknown status
Keywords
ClinConnect Summary
Cornea is an avascular transparent tissue providing refractive power for suitable optical performance. But under the condition of injury or infection, the stable microenvironment of ocular surface has been destroyed. Vessels sprout from the limbus to form corneal neovascularization, becoming an important pathological feature and leading cause of blindness. However, the underlying mechanism particular the inflammation-mediated mechanism remains unclear.
With the advancement of single-cell RNA sequencing (scRNA-seq), the investigation of immune cell transcriptomes has obtained great process ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed ocular chemical injury with or without corneal neovascularization.
- Exclusion Criteria:
- • 1. Those who are diagnosed ocular diseases except for chemical ocular injury, such as uveitis, retinopathy.
- • 2. Those who are diagnosed allergic disease, autoimmune diseases or hematological diseases, infectious disease, such as eczema, systemic lupus erythematosus (SLE), agranulocytosis and viral hepatitis.
- • 3. Those who took immunosuppressive treatments in the past 3 months.
- • 4. Pregnant or nursing women.
- • 5. Those who have serious heart, lung, liver or kidney diseases.
- • 6. Those who have serious systemic diseases.
- • 7. Those who performed ocular surgery (including cataract surgery) in recent three months.
- • 8. Those who have been enrolled in other interventional clinical studies at the same time.
- • 9. Those who are unable to complete the study according to the investigators' requirements.
About Zhongshan Ophthalmic Center, Sun Yat Sen University
The Zhongshan Ophthalmic Center, affiliated with Sun Yat-sen University, is a leading institution in ophthalmic research and clinical care in China. Renowned for its commitment to advancing the field of ophthalmology, the center specializes in innovative treatments and technologies for various eye conditions. With a strong emphasis on clinical trials, the center aims to enhance patient outcomes through rigorous scientific investigation and collaboration with global research networks. Its multidisciplinary team of experts is dedicated to fostering cutting-edge research that translates into effective therapeutic strategies for vision preservation and restoration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials